Home Featured Page 80

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Opinion: How Ayahuasca Could Change You

Natural Medicine Advisory Bulletin #8.1: Recommendation Round-up

Natural Medicine Advisory Bulletin #8: January 2024

Pα+: Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the...

PT486 – 5-MeO-DMT, Somatic Release, and Creating Context for Spirituality

Psychedelic Research Bulletin: January 2024

PT485 – Meeting People Where They Are: Why the Underground Will...

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023

Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer...

Sacred Mycology Summit: A Three Day Online Educational Gathering

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Opinion: How Ayahuasca Could Change You

Natural Medicine Advisory Bulletin #8.1: Recommendation Round-up

Natural Medicine Advisory Bulletin #8: January 2024

Pα+: Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the...

PT486 – 5-MeO-DMT, Somatic Release, and Creating Context for Spirituality

Psychedelic Research Bulletin: January 2024

PT485 – Meeting People Where They Are: Why the Underground Will...

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023

Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer...

Sacred Mycology Summit: A Three Day Online Educational Gathering

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY